A Comparison of Psychotropic Drug Side Effect Profiles in Adults Diagnosed With Intellectual Disabilities and Autism Spectrum Disorders

被引：10
作者：
Hess, Julie [1 ]
Matson, Johnny [1 ]
Neal, Daniene [1 ]
Mahan, Sara [1 ]
Fodstad, Jill [1 ]
Bamburg, Jay [2 ]
Holloway, Jodie [2 ]
机构：
[1] Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA
[2] Pinecrest Supports & Serv Ctr, Pineville, LA USA
来源：
JOURNAL OF MENTAL HEALTH RESEARCH IN INTELLECTUAL DISABILITIES | 2010年 / 3卷 / 02期
关键词：
autism spectrum disorders; drug side effects; Matson Evaluation of Drug Side Effects (MEDS); psychotropic medication; intellectual disability;
D O I：
10.1080/19315861003690588
中图分类号：
G76 [特殊教育];
学科分类号：
040109 ;
摘要：
Forty-eight adults diagnosed with intellectual disabilities and Autistic Disorder or Pervasive Developmental Disorder-Not Otherwise Specified were examined with regard to psychotropic medication side effects. Participants were divided into 4 groups: no psychotropic medication group (n = 9); atypical antipsychotic medication group (n = 13); atypical antipsychotic and antiepileptic drug group (AEDs/mood stabilizers; n = 13); and a group of individuals receiving atypical antipsychotic medication, AEDs/mood stabilizers, and anxiolytics (n = 13). Those participants not currently prescribed any psychotropic medications evinced the fewest side effects. Participants prescribed psychotropic medication across multiple classes evinced more side effects. Thus, persons receiving atypical antipsychotic medication, AEDs/mood stabilizers, and anxiolytics had the greatest number of side effects. More specifically, the greatest number of side effects pertained to the CNS-Parkinsonism/Dyskinesia subscale.
引用
收藏
页码：85 / 96
页数：12
相关论文
共 39 条
  • [1] Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation
    Advokat, CD
    Mayville, EA
    Matson, JL
    [J]. RESEARCH IN DEVELOPMENTAL DISABILITIES, 2000, 21 (01) : 75 - 84
  • [2] Aman M.G., 1988, Psychopharmacology of the Developmental Disabilities
  • [3] PSYCHOTROPIC AND ANTICONVULSANT DRUGS IN SUBJECTS WITH AUTISM - PREVALENCE AND PATTERNS OF USE
    AMAN, MG
    VANBOURGONDIEN, ME
    WOLFORD, PL
    SARPHARE, G
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (12) : 1672 - 1681
  • [4] Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence
    Aman, MG
    De Smedt, G
    Derivan, A
    Lyons, B
    Findling, RL
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (08) : 1337 - 1346
  • [5] [Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787
  • [6] PHARMACOLOGICAL CONTROL OF ABERRANT BEHAVIOR IN THE MENTALLY-RETARDED - TOWARD A MORE RATIONAL APPROACH
    BAUMEISTER, AA
    SEVIN, JA
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1990, 14 (03) : 253 - 262
  • [7] Pervasive developmental disorders in preschool children
    Chakrabarti, S
    Fombonne, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (24): : 3093 - 3099
  • [8] Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities
    de Leon, Jose
    Greenlee, Brian
    Barber, Jack
    Sabaawi, Mohamed
    Singh, Nirbhay N.
    [J]. RESEARCH IN DEVELOPMENTAL DISABILITIES, 2009, 30 (04) : 613 - 669
  • [9] Aggressive behavior in individuals with moderate to borderline intellectual disabilities who live in a residential facility: An evaluation of functional variables
    Embregts, Petri J. C. M.
    Didden, Robert
    Schreuder, Nicole
    Huitink, Cecile
    van Nieuwenhuijzen, M.
    [J]. RESEARCH IN DEVELOPMENTAL DISABILITIES, 2009, 30 (04) : 682 - 688
  • [10] GPOWER: A general power analysis program
    Erdfelder, E
    Faul, F
    Buchner, A
    [J]. BEHAVIOR RESEARCH METHODS INSTRUMENTS & COMPUTERS, 1996, 28 (01): : 1 - 11
1234